- 79-83% in normal testosterone (T) range (FDA requirement 75%)
- No patient elevated beyond normal range
- Androxal's impact on sperm concentration meets FDA non-inferiority threshold compared to placebo
- Potential key points of differentiation from gels
Repros Therapeutics (RPRX) stock is dropping on Tuesday after the FDA asked the company to conduct an additional Phase 3 trial of its enclomiphene drug.